Table 5.
Patients antisera response to peptides derived from TvBspA625.
| T. vaginalis positive patients | T. vaginalis negative patients | |||||
| Female | Male | Totala | Female | Male | Totala | |
| Positive ≥ 1 peptide | 89 | 59 | 148* (88%) | 3 | 7 | 10*(16%) |
| Negative to all peptides | 15 | 6 | 21* (12%) | 33 | 18 | 51* (84%) |
| Total | 104 | 65 | 169 | 36 | 25 | 61 |
| HIV positive | 71 | 56 | 127** (75%) | 15 | 18 | 33** (54%) |
| HIV positive & positive ≥ 1 peptide | 62 | 53 | 115 | 0 | 4 | 4 |
| HIV positive & negative all peptides | 9 | 3 | 12 | 15 | 14 | 29 |
| HIV negative | 33 | 9 | 42** (25%) | 21 | 7 | 28** (46%) |
| HIV negative & positive ≥ 1 peptide | 27 | 6 | 33 | 3 | 3 | 6 |
| HIV negative & negative all peptides | 6 | 3 | 9 | 18 | 4 | 22 |
aA total of 169 patients with sera positive for T. vaginalis total protein extracts were contrasted to 61 patients with sera negative for T. vaginalis total protein extracts. Fractions of respective samples are indicated (in %). The proportion of HIV positive sera from the same set of patients was also compared. Sets of values used for statistical test and calculation of respective % are indicated by * or **.